It was reported yesterday that Castle Creek Pharmaceutical Holdings, Inc, a privately held holding company that holds and invests in companies in the orphan dermatology space, has signed a contract to acquire Fibrocell Science Inc (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases.
Both firms have advanced investigational therapies for the treatment of multiple types of epidermolysis bullosa into late-stage clinical research. FCX-007, Fibrocell's lead gene therapy candidate, is being assessed in a Phase three pivotal trial to treat recessive dystrophic epidermolysis bullosa. In addition, Fibrocell is assessing FCX-013 for the treatment of moderate to severe localised scleroderma in a Phase 1/2 clinical trial. Castle Creek is committed to continuing that research and development. It will also continue Phase 2b development of CCP-020 for epidermolysis bullosa simplex and other forms of epidermolysis bullosa.
Dr Mary Spellman, Chief Medical Officer and Senior Vice President of Research & Development at Castle Creek, said, 'Fibrocell's unique and innovative gene therapy platform provides us with development opportunities that will strengthen the combined company as a leader for EB and other rare conditions where there are limited options for affected patients. We are truly excited about the future of the new company and the benefits we can bring to patients.'
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval